The Latest Breaking News from AbbVie Inc

San Francisco will start a trial against Walgreens Boots Alliance Inc (NASDAQ:WBA) and three other companies accused of fueling an opioid crisis in the city. San Francisco has alleged that Walgreens, Teva Pharmaceutical Industries Ltd (NYSE:TEVA), AbbVie Inc's (NYSE:ABBV) Allergan unit, and Teva-owned Anda Inc created a "public nuisance" by flooding the city with prescription opioids and failing…

Alabama reached $276 million in settlements with Johnson & Johnson (NYSE:JNJ), McKesson Corporation (NYSE:MCK), and Endo International Plc (NASDAQ:ENDP), resolving claims on the opioid addiction crisis, the state attorney general said. McKesson will pay $141 million. JNJ and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement.  The three…

The healthcare industry is well-positioned to ride out a potential recessionary shock, thanks in-part to the inelastic demand for COVID-19 vaccines worldwide. Thus, we think investors could invest in fundamentally sound healthcare stocks Pfizer Inc. (PFE), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Eli Lilly and Company (LLY), and Merck…

Allergan, an AbbVie Inc (NYSE: ABBV) company, announced topline data from Phase 3 VIRGO trial evaluating Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia, age-related blurry near vision.

Rhode Island's attorney general announced settlements worth $107 million against Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and AbbVie Inc's (NYSE: ABBV) Allergan unit to resolve claims over

The FDA approved AbbVie Inc's (NYSE:ABBV) Rinvoq (upadacitinib) for adults patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blockers.  This FDA approval is the first indication for Rinvoq in gastroenterology and is supported by efficacy and safety data from…

AbbVie Inc (NYSE: ABBV) and Gedeon Richter Plc have 

AbbVie Inc (NYSE: ABBV) has reported data from the Phase 3 PROGRESS trial of atogepant (Qulipta) for the 

Ardelyx Inc (NASDAQ:ARDX) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1. Analyst Chris Howerton thinks Ardelyx "stands out" given that the Company has an approved IBS-C product, Isbrela, that will launch in April and whose commercial…